What changed
$ABBV — Develops and sells pharmaceutical drugs.
🎯 Q1 FY26 | Rev $15B | EPS $2.65 vs $2.67 🔴 | Margin 26.6%
💡 Consensus expected adjusted EPS of $2.67, but AbbVie delivered $2.65 – a 0.77% miss. The market may overreact to this small miss, but the underlying business shows revenue growth of 12.4% YoY and operating cash flow more than doubled. The miss is likely noise, not a trend.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 15% to $260 (based on 18x forward EPS of ~$14.50) vs downside 10% to $200 (if growth disappoints). Ratio 1.5:1.
🔮 Catalyst: Next earnings report (likely July 2026): focus on Skyrizi/Rinvoq sales growth and margin recovery. Metric to watch: immunology revenue growth rate >15% YoY. Failure signal: if immunology growth slows below 10% or operating margin declines further.
Also in play: $JNJ $PFE $MRK $LLY $BMY $TMO